Sufferers of Friedreich’s Ataxia face major setback as HSE Drugs Group rejects Skyclarys reimbursement

The Health Service Executive (HSE) Drugs Group in Ireland has formally rejected the reimbursement of Skyclarys, a treatment for the rare genetic condition Friedreich’s Ataxia. This decision represents a significant setback for patients who rely on the state health system to access the medication.

Despite the negative recommendation, the process remains ongoing. A final determination is expected following a scheduled meeting of HSE senior management on August 25, which will review the recommendation before reaching a definitive conclusion.